General Surgery

THE CONCEPT — THE CENTRAL QUESTION IS CANCER

A solitary thyroid nodule is a discrete swelling within one lobe of an otherwise normal-feeling thyroid. It is a common presentation, and the entire work-up is built around answering one question: is it malignant? The reassuring background fact is that only about 5–10% of clinically solitary nodules are cancerous — the great majority are benign — but because a missed thyroid cancer is very treatable when caught, every solitary nodule is assessed systematically rather than dismissed.

WHAT A 'SOLITARY' NODULE ACTUALLY IS

It is worth knowing that many apparently solitary nodules are not truly solitary: the commonest finding is a dominant or prominent nodule within an occult multinodular goitre, or a benign colloid nodule. Genuinely discrete lesions include a benign follicular adenoma, a thyroid cyst, an area of thyroiditis, and — the one to exclude — a thyroid carcinoma.

CLINICAL RED FLAGS FOR MALIGNANCY

The history and examination look specifically for features that raise the probability of cancer:

• Age extremes (under 20 or over 60) and male sex.
• Rapid growth, or a hard, irregular, fixed nodule.
• Hoarseness (suggesting recurrent laryngeal nerve infiltration) or dysphagia/stridor.
• Cervical lymphadenopathy.
• A history of neck irradiation in childhood, or a family history of thyroid cancer or MEN syndrome.

INVESTIGATIONS

The nodule is worked up with a logical sequence of tests:

• Thyroid function tests (TSH, T3, T4) — assess function; a functioning ('toxic') nodule that suppresses the TSH is rarely malignant.
• Ultrasound of the neck — characterises the nodule (solid vs cystic) and looks for suspicious features (microcalcification, hypoechogenicity, irregular margins, increased internal vascularity, taller-than-wide shape) and abnormal nodes.
• Fine-needle aspiration cytology (FNAC) — the single most important investigation, giving a cytological category (Thy/Bethesda) that guides management.
• Radioisotope scan — reserved for a nodule with a suppressed TSH: a 'hot' (functioning) nodule is almost always benign, whereas a 'cold' (non-functioning) nodule carries a ~15–20% malignancy risk.

MANAGEMENT — GUIDED BY CYTOLOGY

Treatment follows the FNAC result. A benign (Thy2) nodule is reassured and observed, with surgery only for size, symptoms or cosmesis. A malignant or suspicious (Thy4/Thy5) nodule is treated by thyroidectomy. The crucial category is the follicular lesion (Thy3): because FNAC cannot distinguish a benign follicular adenoma from a follicular carcinoma, these patients undergo a diagnostic hemithyroidectomy (lobectomy) so the whole lesion can be examined histologically. A simple cyst is aspirated, with excision if it recurs or the fluid is bloodstained.

THE CYTOLOGY CATEGORIES

FNAC results are reported in standardised categories (the Thy or Bethesda system) that directly drive management: Thy1 non-diagnostic (repeat the aspirate), Thy2 benign (reassure/observe), Thy3 follicular/indeterminate (diagnostic hemithyroidectomy), Thy4 suspicious of malignancy, and Thy5 diagnostic of malignancy (proceed to appropriate thyroidectomy). This categorisation is why cytology sits at the centre of the pathway — it converts a lump into a management plan.

THE APPROACH IN SUMMARY

Put together, the assessment of any solitary nodule is a disciplined sequence: clinical evaluation for red flags → thyroid function tests → ultrasound → FNAC (with an isotope scan only if the TSH is suppressed). The great value of this scheme is that it confidently reassures the ~90% with benign disease while reliably selecting the ~10% who need surgery — and it never relies on clinical impression alone, because a hard fixed nodule can occasionally be benign and a deceptively soft one malignant.

CLINICAL EXAMINATION OF THE NODULE

Examination of the neck contributes real information that guides the work-up. The nodule is assessed for size, consistency (soft, firm or hard), surface, mobility, and whether it moves on swallowing (confirming a thyroid origin). The examiner palpates for cervical lymphadenopathy (raising the suspicion of malignancy, especially papillary carcinoma), checks for tracheal deviation and retrosternal extension, listens for a bruit, and assesses the patient's clinical thyroid status. A hard, fixed nodule with palpable nodes and hoarseness is clinically worrying, whereas a soft, mobile, solitary nodule that moves freely is more reassuring — though, as always, imaging and cytology, not clinical feel alone, make the diagnosis.

• Malignancy risk of a clinically solitary nodule ≈ 5–10%; of a 'cold' nodule on scan ≈ 15–20%.
• Follicular lesion on FNAC (Thy3) → diagnostic hemithyroidectomy.
• Hot/toxic nodule → almost always benign.

• Solitary thyroid nodule: the central task is to exclude malignancy (~5–10% are malignant).
• Red flags: age 60, male, rapid growth, hard/fixed, hoarseness, nodes, neck irradiation, family history/MEN.
• Investigate with TFTs, ultrasound, FNAC (most important); isotope scan if TSH suppressed (hot = benign, cold = ~15–20% malignant).
• FNAC cannot distinguish follicular adenoma from carcinoma → follicular lesion needs diagnostic hemithyroidectomy.
• Benign → observe; malignant/suspicious → thyroidectomy; cyst → aspirate (excise if recurs/bloody).

THE CONCEPT — CLASSIFY BY CELL OF ORIGIN & BEHAVIOUR

Thyroid cancers are best understood by their cell of origin, because this determines their behaviour, spread, prognosis and treatment. Most arise from the hormone-producing follicular cells and are called 'differentiated' (papillary and follicular) — these behave well. A distinct group arises from the calcitonin-producing parafollicular C cells (medullary carcinoma), and a rare, lethal group is undifferentiated (anaplastic). Holding this classification in mind makes the whole topic coherent.

THE TYPES

A rare thyroid lymphoma can also arise, characteristically in a gland affected by Hashimoto's thyroiditis.

CLINICAL FEATURES

Most present as a thyroid nodule or swelling, sometimes with features of malignancy — a hard fixed lump, cervical lymphadenopathy, hoarseness (recurrent laryngeal nerve involvement), or dysphagia. Anaplastic carcinoma presents dramatically with a rapidly enlarging hard mass causing stridor, dysphagia and hoarseness from local invasion. Medullary carcinoma may additionally cause flushing and diarrhoea (from calcitonin and other secreted peptides).

INVESTIGATIONS

The nodule is assessed by ultrasound and FNAC with thyroid function tests. For suspected medullary carcinoma, serum calcitonin is a tumour marker, and — critically — the patient is screened for MEN 2 and an associated phaeochromocytoma (plasma/urinary metanephrines) must be excluded and treated before any thyroid surgery, to avoid a hypertensive crisis on the table.

MANAGEMENT

• Differentiated (papillary/follicular) — total thyroidectomy (hemithyroidectomy for small, low-risk papillary tumours), with neck dissection for involved nodes; radioiodine (I-131) ablation of residual/metastatic thyroid tissue; lifelong thyroxine to suppress TSH (removing the growth stimulus); and serum thyroglobulin as a follow-up marker of recurrence.
• Medullary — total thyroidectomy with central compartment node dissection; it does not take up iodine, so radioiodine is ineffective; follow up with calcitonin.
• Anaplastic — usually palliative (airway protection/tracheostomy, external radiotherapy, chemotherapy), as cure is rarely possible.

STAGING & PROGNOSTIC FACTORS

Prognosis in differentiated cancer depends less on the tumour type than on patient and tumour factors captured in scoring systems (such as AMES/AGES): Age (older patients do worse), Metastases, Extent of the primary/extrathyroidal spread, and Size. This is why a young woman with node-positive papillary cancer still has an excellent outlook, whereas the same histology in an older patient with extrathyroidal extension is treated far more aggressively.

FOLLOW-UP & RECURRENCE

After treatment of differentiated cancer, follow-up exploits the biology: having removed all normal thyroid tissue, any detectable serum thyroglobulin (or a rising level) signals recurrent or residual tumour, and whole-body radioiodine scans can localise it. For medullary cancer the equivalent markers are calcitonin and CEA. Lifelong follow-up is standard because differentiated cancers can recur years later, and recurrence is often still curable.

MANAGEMENT OF ADVANCED & RECURRENT DISEASE

Advanced differentiated cancer with distant metastases is still often treatable because the tissue may take up radioiodine: metastases in bone or lung can be targeted with therapeutic I-131 after total thyroidectomy, alongside TSH-suppressive thyroxine. Where tumours dedifferentiate and lose iodine avidity, or in progressive medullary and anaplastic disease, newer targeted kinase inhibitors (e.g. against the RET or BRAF pathways) have a role. External-beam radiotherapy is used for unresectable or symptomatic local disease. The overarching principle is that differentiated thyroid cancer, even when advanced, frequently follows an indolent course and is managed with a long-term outlook.

A NOTE ON PRESENTATION VIA NODES

An important clinical pearl is that differentiated thyroid cancer, especially papillary, may first present as a lateral cervical lymph node rather than a thyroid lump — a firm neck node in a young adult should prompt assessment of the thyroid. Conversely, the finding of thyroid cancer mandates careful assessment of the neck nodal levels, because nodal disease guides the extent of surgery. This bidirectional relationship between the gland and the neck nodes is central to planning the correct operation.

• Differentiated cancer: total thyroidectomy + radioiodine ablation + TSH-suppressive thyroxine; thyroglobulin as marker.
• Medullary: total thyroidectomy + central node dissection; calcitonin marker; NO radioiodine.
• Exclude phaeochromocytoma before medullary/MEN thyroid surgery.

• Classify by origin: differentiated (papillary, follicular — follicular cells), medullary (C cells), anaplastic (undifferentiated), lymphoma (Hashimoto's).
• Papillary (commonest, young, lymphatic spread, excellent prognosis); follicular (blood spread to bone/lung, needs histology).
• Medullary: secretes calcitonin, sporadic or MEN 2 (RET) — screen for phaeochromocytoma first; anaplastic: elderly, rapidly fatal.
• Differentiated → total thyroidectomy + radioiodine + TSH suppression + thyroglobulin follow-up.
• Medullary → total thyroidectomy + central node dissection, no radioiodine; anaplastic → palliative.

THE CONCEPT & CLASSIFICATION

A goitre is simply an enlargement of the thyroid gland, and the many causes become manageable if classified along two axes: whether the gland is diffusely enlarged or nodular, and whether it is toxic (overactive) or non-toxic. This grid organises the whole subject.

HOW A SIMPLE GOITRE BECOMES MULTINODULAR

Understanding the natural history explains most nodular goitres. Iodine deficiency (or increased demand at puberty/pregnancy) lowers thyroid hormone output, so the pituitary secretes more TSH, which drives diffuse hyperplasia — a soft, smooth simple goitre. Over years of fluctuating stimulation and involution, the gland becomes nodular (multinodular goitre), with some nodules eventually becoming autonomous (toxic MNG) and others developing haemorrhage, cystic change or calcification. This is why endemic (iodine-deficient) regions have so much goitre, and why simple goitres evolve into nodular ones.

CLINICAL FEATURES

A goitre is a neck swelling that characteristically moves upwards on swallowing (because the thyroid is bound to the larynx by the pretracheal fascia) — the sign that identifies it as thyroid. Examination assesses its size, surface (diffuse or nodular), consistency, lower border (whether it can be felt, or extends retrosternally), any tracheal deviation or compression, cervical nodes, a bruit, and the patient's thyroid status.

COMPLICATIONS

These are high-yield and follow from a mass in the neck: pressure effects — dysphagia (oesophagus), dyspnoea and stridor (tracheal compression), and hoarseness (recurrent laryngeal nerve); retrosternal extension causing thoracic-inlet obstruction; secondary thyrotoxicosis (toxic change); malignant change; and haemorrhage into a nodule, causing sudden painful enlargement that may acutely compress the airway.

INVESTIGATIONS & MANAGEMENT

Investigate with thyroid function tests, ultrasound, FNAC of any dominant/suspicious nodule, and CT (without iodinated contrast if radioiodine may be needed) to assess retrosternal extension and tracheal compression. A non-toxic simple goitre is usually observed (correcting iodine deficiency). Surgery (total or subtotal thyroidectomy) is indicated for pressure symptoms, retrosternal extension, cosmetic concern, suspected malignancy, or toxic change; toxic goitres are additionally managed with antithyroid drugs or radioiodine.

THE THYROIDITIDES

Several forms of thyroiditis cause a diffuse goitre and are worth distinguishing. Hashimoto's thyroiditis is an autoimmune condition causing a firm diffuse goitre and eventual hypothyroidism (and carries a small risk of thyroid lymphoma). De Quervain's (subacute) thyroiditis is a painful goitre following a viral infection, with a transient thyrotoxic phase and a raised ESR, that is usually self-limiting. Riedel's thyroiditis is a rare, dense fibrosis producing a hard, fixed ('woody') gland that mimics cancer and can compress adjacent structures.

RETROSTERNAL GOITRE

A retrosternal (substernal) goitre is one that extends behind the sternum into the mediastinum, usually as a lower extension of a multinodular goitre. It matters because the confined thoracic inlet means it readily causes tracheal compression and venous obstruction (revealed by Pemberton's sign). It is an indication for surgery, and although it looks alarming, the great majority can be delivered through a standard neck (cervical) incision.

ASSESSMENT OF THYROID STATUS & AIRWAY

Any goitre is assessed for two practical things beyond its size: the patient's thyroid status (euthyroid, hypothyroid or thyrotoxic — because a toxic goitre must be controlled before surgery) and the airway. Longstanding large goitres, especially retrosternal ones, may compress or deviate the trachea and, over time, weaken the tracheal cartilage rings (tracheomalacia), which can collapse when the supporting goitre is removed. Pre-operative assessment therefore includes flow-volume loops or CT where compression is suspected, and the anaesthetist is forewarned, because airway management is the key peri-operative risk in large goitre surgery.

HASHIMOTO'S & THE RISK OF LYMPHOMA

Hashimoto's thyroiditis deserves a further note because, besides being the commonest cause of hypothyroidism and a firm diffuse goitre, it carries a small but definite risk of primary thyroid lymphoma. A rapidly enlarging goitre in a patient with known Hashimoto's should therefore raise this suspicion and prompt biopsy, illustrating how a benign autoimmune goitre can occasionally harbour a serious complication.

• Goitre = thyroid enlargement; classify as diffuse vs nodular and toxic vs non-toxic; moves up on swallowing.
• Iodine deficiency → ↑TSH → diffuse hyperplasia (simple goitre) → over years → multinodular goitre → can become toxic.
• Complications: pressure (dysphagia, stridor/dyspnoea, hoarseness), retrosternal extension (Pemberton's sign), toxic change, malignancy, haemorrhage into a nodule.
• Investigate: TFTs, ultrasound, FNAC of dominant nodule, CT for retrosternal/tracheal compression.
• Surgery for pressure symptoms, retrosternal extension, cosmesis, suspected malignancy or toxic change.

THE CONCEPT

Thyrotoxicosis is the clinical state produced by an excess of circulating thyroid hormone, and its features flow directly from the fact that thyroid hormone drives the body's metabolic rate and amplifies sympathetic activity. The commonest cause is Graves' disease, an autoimmune condition in which TSH-receptor stimulating antibodies continuously activate the gland — explaining both the diffuse overactivity and the unique extrathyroidal features.

CAUSES

The main causes are Graves' disease (diffuse, autoimmune — commonest), toxic multinodular goitre (autonomous nodules in an older patient), toxic adenoma (a single hot nodule), and thyroiditis (a transient release of stored hormone). Recognising the cause matters because it determines treatment.

CLINICAL FEATURES

The hypermetabolic, sympatho-active state produces a characteristic picture: weight loss despite a good appetite, heat intolerance and sweating, palpitations with tachycardia or atrial fibrillation, a fine tremor, anxiety and irritability, diarrhoea, oligomenorrhoea, warm moist skin, and proximal muscle weakness. A goitre is usually present.

FEATURES SPECIFIC TO GRAVES' DISEASE

Because Graves' is autoimmune, it has extrathyroidal signs not seen in other causes, which are diagnostic: eye disease (Graves' ophthalmopathy) — exophthalmos/proptosis, lid retraction and lid lag, and, in severe cases, ophthalmoplegia and sight-threatening optic-nerve compression; pretibial myxoedema (thickened skin over the shins); thyroid acropachy (clubbing-like changes); and a diffuse goitre with an audible bruit (from its vascularity).

INVESTIGATIONS

Confirm with thyroid function tests — a suppressed TSH with raised free T3/T4. TSH-receptor antibodies confirm Graves'. A radioiodine uptake scan distinguishes the causes: diffusely increased uptake in Graves', patchy uptake in toxic MNG, and a single hot area in a toxic adenoma.

MANAGEMENT — THREE MODALITIES

• Antithyroid drugs — carbimazole (or propylthiouracil) block hormone synthesis and render the patient euthyroid, given as a titrated dose or 'block-and-replace'; a 12–18 month course achieves lasting remission in about half of Graves' patients. A beta-blocker (propranolol) rapidly controls the sympathetic symptoms. Patients must be warned that a sore throat may signal agranulocytosis and to have a blood count checked.
• Radioiodine (I-131) — a definitive outpatient treatment that ablates thyroid tissue; it commonly results in hypothyroidism, and is avoided in pregnancy and active eye disease.
• Surgery (thyroidectomy) — for a large or compressive goitre, suspected malignancy, failed drug therapy, or patient choice. The gland must be rendered euthyroid before operation and given Lugol's iodine pre-operatively to reduce its vascularity.

CHOOSING BETWEEN THE THREE TREATMENTS

Each modality has trade-offs that guide the choice. Antithyroid drugs are non-invasive and can achieve lasting remission in Graves' but require prolonged treatment and carry a relapse rate and the risk of agranulocytosis. Radioiodine is simple and definitive but usually leads to lifelong hypothyroidism and is unsuitable in pregnancy or active eye disease. Surgery gives rapid, definitive control and is preferred for large/compressive goitres, suspected malignancy, or when the other options fail or are contraindicated, at the cost of the operative risks. The decision is individualised to the cause, goitre size, eye disease, pregnancy plans and patient preference.

GRAVES' OPHTHALMOPATHY & PREGNANCY

Graves' eye disease is autoimmune and runs a course partly independent of the thyroid; it is worsened by smoking and by radioiodine, and severe, sight-threatening disease needs high-dose steroids, orbital radiotherapy or surgical decompression. In pregnancy, propylthiouracil is generally preferred in the first trimester and radioiodine is contraindicated — an important safety point.

THYROTOXICOSIS IN SPECIAL SITUATIONS

Two situations deserve emphasis. In pregnancy, thyrotoxicosis must be controlled to protect mother and fetus, but radioiodine is absolutely contraindicated (it crosses the placenta and ablates the fetal thyroid), so antithyroid drugs are used — propylthiouracil in the first trimester — at the lowest effective dose, with surgery reserved for drug failure. In the elderly, thyrotoxicosis may present atypically as 'apathetic thyrotoxicosis' — with weight loss, atrial fibrillation and lethargy rather than the classic hyperkinetic picture — so it must be actively considered as a cause of new atrial fibrillation or unexplained weight loss in older patients.

• Carbimazole to render euthyroid; propranolol for sympathetic symptoms; warn re agranulocytosis (sore throat → FBC).
• Lugol's iodine ~10 days pre-op to reduce gland vascularity.
• Radioiodine avoided in pregnancy and active Graves' eye disease.

• Thyrotoxicosis = excess thyroid hormone → hypermetabolic + sympathetic features; Graves' (autoimmune, TSH-receptor antibodies) is commonest.
• Causes: Graves', toxic MNG, toxic adenoma, thyroiditis.
• Features: weight loss with good appetite, heat intolerance, palpitations/AF, tremor, anxiety, diarrhoea; Graves'-specific: eye disease, pretibial myxoedema, acropachy, diffuse goitre with bruit.
• Diagnose: low TSH + high T3/T4, TSH-receptor antibodies, radioiodine uptake scan (diffuse/patchy/single-hot).
• Treat with antithyroid drugs (carbimazole) + propranolol, radioiodine, or surgery; render euthyroid + Lugol's iodine before surgery to prevent thyroid storm.

THE CONCEPT — ANATOMY & TIMING

The complications of thyroidectomy are best learned through the anatomy of the structures the surgeon works around and the timing at which each appears. The thyroid is intimately related to the recurrent and external laryngeal nerves, the parathyroid glands, the trachea and major vessels, and damage to any of these produces a characteristic, often examinable, complication.

HAEMORRHAGE & TENSION HAEMATOMA

Reactionary haemorrhage into the closed neck space is the most urgent early complication. Because the neck is a confined compartment, an expanding tension haematoma compresses the trachea and causes rapid airway obstruction — a true emergency. The life-saving action is to open the wound immediately at the bedside (removing skin and strap-muscle sutures) to release the haematoma and relieve the airway, before returning to theatre.

NERVE INJURIES

• Recurrent laryngeal nerve (RLN) — runs in the tracheo-oesophageal groove near the inferior thyroid artery. Unilateral injury causes hoarseness (a paralysed vocal cord); bilateral injury is an emergency causing stridor and airway obstruction (both cords paralysed near the midline), often requiring re-intubation or tracheostomy.
• External (superior) laryngeal nerve — near the superior thyroid pedicle; injury weakens the cricothyroid muscle, causing loss of vocal pitch and voice fatigue — particularly disabling for singers.

HYPOCALCAEMIA

The parathyroid glands may be inadvertently removed or devascularised, causing hypoparathyroidism and a fall in serum calcium, typically at 24–72 hours. This produces neuromuscular irritability — perioral tingling, paraesthesiae, carpopedal spasm, and positive Chvostek's and Trousseau's signs — and, if severe, tetany and laryngospasm. It is usually transient but can be permanent after total thyroidectomy.

AIRWAY PROBLEMS & THYROID STORM

Airway obstruction can result from a haematoma, bilateral RLN palsy, laryngeal oedema, or tracheomalacia (softened tracheal rings after a long-standing large goitre, collapsing when support is removed). In an inadequately prepared thyrotoxic patient, the operation can precipitate a thyroid storm.

LATE COMPLICATIONS

Later problems include hypothyroidism (inevitable after total thyroidectomy; may also develop after subtotal resection), recurrent thyrotoxicosis or goitre after subtotal surgery, permanent hypoparathyroidism or RLN palsy, and a hypertrophic or keloid scar.

TYPES OF THYROIDECTOMY

The operation performed depends on the pathology, and each carries its own risk profile. A hemithyroidectomy (lobectomy) removes one lobe (diagnostic for a follicular lesion, or treatment for benign unilateral disease). A total thyroidectomy removes the whole gland (for cancer or large bilateral goitre) but carries the highest risk of bilateral nerve injury and permanent hypoparathyroidism. A subtotal thyroidectomy (leaving a remnant) was traditionally used for Graves'/goitre to preserve function but risks recurrence. Matching the operation to the disease balances cure against the risk of these complications.

PREVENTION & POST-OPERATIVE MONITORING

Most complications are minimised by careful technique — identifying and preserving the recurrent laryngeal nerves and parathyroid glands (with auto-transplantation of a devascularised parathyroid), meticulous haemostasis, and pre-operative preparation of thyrotoxic patients. Post-operatively the patient is watched for airway compromise and neck swelling (with clip-removers/suture-cutters kept at the bedside for a haematoma), and serum calcium is checked; vocal-cord function is assessed if the voice is abnormal.

MINIMISING RISK & CONSENT

Because these complications are well defined, safe thyroid surgery rests on prevention and informed consent. The surgeon routinely identifies and preserves the recurrent laryngeal nerves and parathyroid glands, uses meticulous haemostasis to prevent a haematoma, and prepares thyrotoxic patients to be euthyroid. Some units use intra-operative nerve monitoring to help protect the recurrent laryngeal nerve. The patient should be consented specifically for the risks of voice change (nerve injury), low calcium (hypoparathyroidism), bleeding, and lifelong thyroxine, so that these recognised outcomes are understood in advance rather than discovered afterwards.

• Airway-threatening neck haematoma → open the wound at the bedside immediately.
• Check serum calcium post-op; severe hypocalcaemia → IV calcium gluconate + oral calcium/vitamin D.
• Unilateral RLN palsy → hoarseness; bilateral → stridor/airway emergency.

• Learn complications by anatomy (nerves, parathyroids, trachea, vessels) and timing (immediate/early/late).
• Tension haematoma → rapid airway obstruction → open the wound at the bedside immediately (emergency).
• RLN injury: unilateral = hoarseness, bilateral = stridor/airway emergency; external laryngeal nerve = loss of voice pitch (singers).
• Hypocalcaemia (parathyroid injury) at 24–72 h: perioral tingling, carpopedal spasm, Chvostek's/Trousseau's → calcium ± vitamin D.
• Also airway obstruction (haematoma/bilateral RLN/tracheomalacia), thyroid storm (unprepared), and late hypothyroidism/recurrence/keloid.